Myelodysplastic Syndrome Treatment Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 6.50 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Myelodysplastic Syndrome Treatment Market Analysis
The myelodysplastic syndrome (MDS) treatment market is projected to register a CAGR of 6.5% during the forecast period, 2022-2027.
The COVID-19 (SARS-CoV-2) pandemic has had a variety of effects on cancer patients, including diagnostic and treatment delays, blood product scarcity, and, most importantly, increased morbidity and mortality from viral infection. For instance, as per the article titled "Myelodysplastic Syndromes (MDS) & COVID-19: Clinical Experience from the United States Epicenter of the Pandemic", published in November 2020, records were reviewed of all patients seen in the MDS clinic of a large New York City tertiary academic medical center between March 12 and May 07, 2020. Among 85 patients seen in the clinic, 23 were found to have COVID-19. Nonetheless, such factors ultimately affected cancer care, causing the therapeutic pathway for MDS patients to be disrupted. This disruption to standard clinical care was exacerbated by the fear that COVID-19 would increase morbidity and mortality in immunocompromised MDS patients. There were fewer data available to guide treatment or protective recommendations in the early days of the pandemic, and advice was limited to expert opinion. Care interruptions had manifested as limited access to laboratory appointments for blood work assessment patients whose diseases required close observation and monitoring. Thus, the blood shortage had a significant impact on patients who required transfusional support, particularly those who lived in regions with few transfusion facilities. Patients undergoing chemotherapy also had to contend with shortened clinic or infusion center hours and inaccessible providers.
Furthermore, ongoing concern among chemotherapy patients that the resulting immunosuppression could make them more susceptible to COVID-19 infection and severe disease has shifted the balance between the risks and benefits of chemotherapy in many cases. As a result of the COVID-19 pandemic, the market studied has been impacted to a greater extent. However, with ongoing vaccinations and decreasing COVID-19 cases, the market studied is expected to regain its full potential during the forecast period.
The global market for myelodysplastic syndrome (MDS) treatment is expected to grow significantly over the coming years, owing to rising pipeline products and product approvals, as well as increased R&D investments in the development of novel drugs for MDS. For instance, Inqovi (decitabine and cedazuridine) tablets were approved by the United States Food and Drug Administration in July 2020 for the treatment of adult patients with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). This is a significant advancement in treatment options for patients with MDS, a type of blood cancer which previously required intravenous therapy at a healthcare facility.
Thus, the aforementioned factors are anticipated to contribute to the growth of the myelodysplastic syndrome (MDS) treatment market. However, side effects associated with the medications are likely to impede the market's growth.
Myelodysplastic Syndrome Treatment Market Trends
This section covers the major market trends shaping the Myelodysplastic Syndrome (MDS) Treatment Market according to our research experts:
The Stem Cell Transplant Segment is Expected to Hold a Major Market Share in the Myelodysplastic Syndrome (MDS) Treatment Market
For patients with myelodysplastic syndromes, stem cell transplantation (SCT) offers a potentially beneficial therapy. There are two major types of SCT, one is an allogeneic stem cell transplant, and the other is an autologous stem cell transplant. In an allogeneic stem cell transplant, after the bone marrow is destroyed, the patient receives blood-forming stem cells from another person, the donor. This is the most common type of transplant for MDS. For instance, the study titled "Allogeneic stem cell transplantation may overcome the adverse impact of myelofibrosis on the prognosis of myelodysplastic syndrome" published on PubMed.gov in August 2021, concluded that patients with myelofibrosis (MF)-2/3 had a worse prognosis than those with myelofibrosis (MF)-0/1 in patients without allogeneic hematopoietic stem cell transplantation (allo-HSCT).
However, allogeneic SCTs can have serious, even life-threatening, side effects; thus, they are usually performed on younger, healthier patients. Patients in their 60s and even 70s have had successful transplants, but SCT is usually done with less intensive (reduced intensity) chemotherapy and/or radiation in older patients. Lower doses may not kill all bone marrow cells, but they are just enough to allow donor cells to take root and grow in the marrow. The lower doses also result in fewer side effects, making this type of transplant more tolerable for older patients. Even so, some serious side effects remain a possibility.
Additionally, patients receive their own stem cells after an autologous stem cell transplant (which were removed before treatment). As the patient's bone marrow contains abnormal stem cells, this type of transplant is rarely used for MDS patients.
Thus, the abovementioned factors are expected to impact the segment's growth over the analysis period.
North America is Expected to Hold a significant share in the market and is expected to do the Same in the Forecast Period.
North America dominates the global myelodysplastic syndrome (MDS) treatment market owing to the increase in the prevalence of myelodysplastic syndrome, early adoption of novel treatments, high R&D investments in the development of novel drugs, and the presence of sophisticated healthcare infrastructure. According to the American Society of Clinical Oncology (ASCO) 2022, MDS affects about 10,000 people in the United States each year. MDS is rare in people under the age of 50. However, people in their 70s are the most likely to develop it. The number of people diagnosed with MDS each year is expected to rise as the United States population ages.
Moreover, product approvals are increasing at a rapid pace, which is helping to drive market growth. Takeda Pharmaceutical Company Limited, for instance, announced in July 2020 that the FDA had granted Breakthrough Therapy Designation to its investigational drug pevonedistat for the treatment of patients with higher-risk myelodysplastic syndromes (HR-MDS). Pevonedistat, a first-in-class NEDD8-activating enzyme (NAE) inhibitor, could be the first new treatment for HR-MDS patients in over a decade, expanding treatment options previously limited to HMA monotherapy. Even with current treatment options, people with HR-MDS continue to have poor outcomes. Likewise, Novartis announced in November 2021 that the United States Food and Drug Administration (FDA) had granted fast-track designation for sabatolimab (MBG453) used in the treatment of adult patients with myelodysplastic syndromes (MDS) defined by an IPSS-R risk category of high or very high risk in combination with hypomethylating agents. Similarly, in September 2020, Gilead Sciences, Inc. announced that the United States Food and Drug Administration (FDA) had granted magrolimab, a first-in-class, investigational anti-CD47 monoclonal antibody for the treatment of newly diagnosed myelodysplastic syndrome, a Breakthrough Therapy designation.
Furthermore, rising patient awareness in the United States is expected to drive market growth over the forecast period. For instance, in September 2020, Jazz Pharmaceuticals plc announced the launch of Find the Right Fit, a patient education program in the United States developed in collaboration with the Myelodysplastic Syndromes (MDS) Foundation, Inc. and the Cancer Support Community to empower people with secondary acute myeloid leukemia (sAML) and MDS.
These factors together are likely to bolster the growth of the myelodysplastic syndrome (MDS) treatment market in the North American region.
Myelodysplastic Syndrome Treatment Industry Overview
In the Myelodysplastic Syndrome (MDS) Treatment Market, major players are focused on expanding their business in different areas by adopting various market strategies, such as partnerships, collaborations, acquisitions, and mergers. Some of the major players operating in the market include AbbVie, Accord Healthcare, Bristol-Myers Squibb, Celgene Corporation, Takeda Pharmaceutical Company Limited, and Novartis AG, among others.
Myelodysplastic Syndrome Treatment Market Leaders
-
Takeda Pharmaceutical Company Limited
-
Bristol-Myers Squibb
-
LUPIN
-
Accord Healthcare
-
Otsuka America Pharmaceutical, Inc.
*Disclaimer: Major Players sorted in no particular order
Myelodysplastic Syndrome Treatment Market News
- In February 2022 The United States Food and Drug Administration (FDA) granted an Orphan drug designated to Syros pharmaceuticals oral therapy, tamibarotene to treat myelodysplastic syndrome (MDS).
- In January 2022, Accord Healthcare announced the UK launch of generic lenalidomide, available for the treatment of adult patients with multiple myeloma, myelodysplastic syndromes, mantle cell lymphoma, and follicular lymphoma, as either a monotherapy or combination therapy.
Myelodysplastic Syndrome Treatment Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 High R&D Investments on the Development of Novel Treatments for MDS
4.2.2 Strong Presence of Pipeline Drugs
4.3 Market Restraints
4.3.1 Side Effects Associated with the Medications
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Treatment Type
5.1.1 Chemotherapy
5.1.2 Immune Treatments
5.1.3 Stem Cell Transplant
5.1.4 Other Treatment Types
5.2 By End User
5.2.1 Hospitals
5.2.2 Specialty Clinics
5.2.3 Other End Users
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AbbVie Inc.
6.1.2 Accord Healthcare
6.1.3 Bristol-Myers Squibb
6.1.4 Jazz Pharmaceuticals Inc.
6.1.5 Novartis AG
6.1.6 Lupin Pharmaceuticals
6.1.7 Otsuka America Pharmaceutical Inc.
6.1.8 Onconova Therapeutics
6.1.9 Takeda Pharmaceutical Company Limited
6.1.10 Astex Pharmaceuticals, Inc.
6.1.11 Amgen Inc.
6.1.12 Hikma Pharmaceuticals PLC
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Myelodysplastic Syndrome Treatment Industry Segmentation
As per the scope of the report, myelodysplastic syndrome (MDS) is a group of diverse bone marrow disorders in which the bone marrow does not produce enough healthy blood cells. MDS is often referred to as a "bone marrow failure disorder." These disorders are characterized by ineffective hematopoiesis, including abnormalities in proliferation, differentiation, and apoptosis. The Myelodysplastic Syndrome (MDS) Treatment Market is segmented by Treatment Type (Chemotherapy, Immune Treatments, Stem Cell Transplant, Other Treatment Types), End-User (Hospitals, Specialty Clinics, and Other End Users), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (USD million) for the above segments.
| By Treatment Type | |
| Chemotherapy | |
| Immune Treatments | |
| Stem Cell Transplant | |
| Other Treatment Types |
| By End User | |
| Hospitals | |
| Specialty Clinics | |
| Other End Users |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Myelodysplastic Syndrome Treatment Market Research FAQs
What is the current Myelodysplastic Syndrome (MDS) Treatment Market size?
The Myelodysplastic Syndrome (MDS) Treatment Market is projected to register a CAGR of 6.5% during the forecast period (2024-2029)
Who are the key players in Myelodysplastic Syndrome (MDS) Treatment Market?
Takeda Pharmaceutical Company Limited , Bristol-Myers Squibb, LUPIN, Accord Healthcare and Otsuka America Pharmaceutical, Inc. are the major companies operating in the Myelodysplastic Syndrome (MDS) Treatment Market.
Which is the fastest growing region in Myelodysplastic Syndrome (MDS) Treatment Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Myelodysplastic Syndrome (MDS) Treatment Market?
In 2024, the North America accounts for the largest market share in Myelodysplastic Syndrome (MDS) Treatment Market.
What years does this Myelodysplastic Syndrome (MDS) Treatment Market cover?
The report covers the Myelodysplastic Syndrome (MDS) Treatment Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Myelodysplastic Syndrome (MDS) Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Medical X-Ray Equipment and Imaging Software Industry Report
Statistics for the 2024 Medical X-Ray Equipment and Imaging Software market share, size and revenue growth rate, created by 糖心vlog传媒鈩� Industry Reports. Medical X-Ray Equipment and Imaging Software analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
